about
Cisplatin ototoxicity and protection: clinical and experimental studiesMolecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothioneinsiRNA-mediated knock-down of NOX3: therapy for hearing loss?Cisplatin exposure damages resident stem cells of the mammalian inner ear.The design and screening of drugs to prevent acquired sensorineural hearing lossRole of the copper transporter, CTR1, in platinum-induced ototoxicity.Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study.An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo.Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.The protective role of molsidomine on the Cisplatin-induced ototoxicityCisplatin-based therapy: a neurological and neuropsychological review.Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.Nanocarriers for delivery of platinum anticancer drugs.Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.OTOTOXIC EFFECTS OF CARBOPLATIN IN ORGANOTYPIC CULTURES IN CHINCHILLAS AND RATSPlatinum drugs in the treatment of non-small-cell lung cancerProtective effect of metformin against cisplatin-induced ototoxicity in an auditory cell line.Using the zebrafish lateral line to uncover novel mechanisms of action and prevention in drug-induced hair cell deathMixed ligand μ-phenoxo-bridged dinuclear copper(II) complexes with diimine co-ligands: efficient chemical nuclease and protease activities and cytotoxicity.Bucillamine prevents cisplatin-induced ototoxicity through induction of glutathione and antioxidant genes.Platinum-induced neurotoxicity and preventive strategies: past, present, and futurePharmacogenomics of cisplatin-induced ototoxicityMixed ligand copper(II) dicarboxylate complexes: the role of co-ligand hydrophobicity in DNA binding, double-strand DNA cleavage, protein binding and cytotoxicity.Neurotoxicity caused by the treatment with platinum analogues.The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear.New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descentAssociation between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patientsRelationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugsSphingosine 1-phosphate receptor 2 (S1P2) attenuates reactive oxygen species formation and inhibits cell death: implications for otoprotective therapyMC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.Self-Reported Hearing in the Last 2 Years of Life in Older Adults.Platinum neurotoxicity pharmacogeneticsProgress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy.Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearanceA novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo.Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in miceComparative nephrotoxicity of Cisplatin and nedaplatin: mechanisms and histopathological characteristics.
P2860
Q24628775-BAE56CC5-58F0-4053-80C8-9CE267B2DF28Q24798557-D35FD9C7-2B04-4E25-9A76-94E9FB0CC01FQ30355898-B7BCC55E-8162-4229-B762-C5650D370646Q30401803-A7710135-3729-42B6-965C-38A1F032BCDFQ30465748-DFC98AEA-6C94-4016-8F9C-B509EC228DB3Q30477867-11C1B583-6C4B-452B-97AF-9A9B4B509E28Q33601281-45C4E899-5246-4AFB-B6DE-6EF175893011Q33615268-E3F6C96D-E13B-4792-B7C3-752D5F88B06EQ33669579-EF257EEF-79E1-48E4-BB61-55F38ADE30E7Q33808425-F5E23058-F624-477A-8E7C-3E394DB5A119Q33833882-67F52AC5-2F8E-4679-AE0E-E4205861CFB2Q34110153-20EBECED-7E97-4047-9C29-5477815858E2Q34338695-EFD2F85C-D029-441D-B2A4-7ED8D3DCFBC8Q34653461-E8C9788F-4A88-45AD-97E7-52664A67C40BQ34925061-F036F9E8-6E5A-40C9-9BB5-DDB6D936F249Q34954760-B0192887-99F3-4875-8EEE-E5836C191F6DQ35057783-D97195DC-8614-402F-8281-69E6EB012062Q35094539-1BEC6C0F-F4E2-43DD-859E-13FCB831BB9DQ35111438-E32BA627-2F6D-4D8C-8EB2-17A484A13FF7Q35137650-DF22D39F-EE06-4148-88C7-7587A65CA15BQ35345734-B3B15002-6775-40EE-B49F-5F626D29A2E1Q35553827-EAC58982-C489-4494-B9C8-17F0C5AA44ECQ35625019-07FCC17B-6C3D-4229-90C5-2EC1C11ED504Q35692169-7C46B95C-FEA2-4883-A200-E800C236EA28Q36171348-A4875C4B-5E25-4FB5-B3F1-EF68F82C75EAQ36291281-FEF87CE7-42E7-4FE2-8296-D9F741F58AAFQ36344699-A66A16DC-8E36-409C-A51F-AB937B4760BCQ36384257-61102F0E-5081-49D6-A07C-7AC7829CA5D4Q36629248-84893FF4-2FB2-4776-8B23-6E508D31A44AQ36641336-D2C3972A-58F3-4336-8849-3B166FC0CF9AQ36772043-47167897-B424-4053-982F-8B29DD753B2BQ36799651-47CBCB00-DD64-4E81-BBAB-D9E5023C6A12Q37082272-CDD6B1B0-C1D3-4230-9F21-F76958B73325Q37088660-54EA67F4-EFE8-4FEC-A242-D89720153752Q37118862-F449E54F-29B4-46F4-9C5B-87DD6ABCA61DQ37283689-9FDA5451-1248-44BF-B6DF-7CE03774173CQ37320350-46624DFE-FC9C-4676-BDDC-40C6DA274354Q37470083-E4EEF17D-CA02-4710-B8F2-D3C1CF1E2AD1Q37568467-CC036DE2-BD2F-4F26-BBE5-D2311E96E31AQ37978306-1BB8FEBF-231A-4BAD-941F-B15766ECF029
P2860
description
1995 nî lūn-bûn
@nan
1995 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Comparative adverse effect profiles of platinum drugs.
@ast
Comparative adverse effect profiles of platinum drugs.
@en
type
label
Comparative adverse effect profiles of platinum drugs.
@ast
Comparative adverse effect profiles of platinum drugs.
@en
prefLabel
Comparative adverse effect profiles of platinum drugs.
@ast
Comparative adverse effect profiles of platinum drugs.
@en
P1433
P1476
Comparative adverse effect profiles of platinum drugs
@en
P2093
M J McKeage
P304
P356
10.2165/00002018-199513040-00003
P577
1995-10-01T00:00:00Z
P6179
1031869837